Towards a blood-stage vaccine for malaria: Are we following all the leads?

被引:94
作者
Good, MF [1 ]
机构
[1] Queensland Inst Med Res, Cooperat Res Ctr Vaccine Technol, Bancroft Ctr, Herston, Qld 4006, Australia
关键词
D O I
10.1038/35100540
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Although the malaria parasite was discovered more than 120 years ago, it is only during the past 20 years, following the cloning of malaria genes, that we have been able to think rationally about vaccine design and development. Effective vaccines for malaria could interrupt the life cycle of the parasite at different stages in the human host or in the mosquito. The purpose of this review is to outline the challenges we face in developing a vaccine that will limit growth of the parasite during the stage within red blood cells - the stage responsible for all the symptoms and pathology of malaria. More than 15 vaccine trials have either been completed or are in progress, and many more are planned. Success in current trials could lead to a vaccine capable of saving more than 2 million lives per year.
引用
收藏
页码:117 / 125
页数:9
相关论文
共 115 条
[71]   ANTIGENS INDUCED ON ERYTHROCYTES BY PLASMODIUM-FALCIPARUM - EXPRESSION OF DIVERSE AND CONSERVED DETERMINANTS [J].
MARSH, K ;
HOWARD, RJ .
SCIENCE, 1986, 231 (4734) :150-153
[72]  
Metzger WG, 1999, PARASITE IMMUNOL, V21, P335, DOI 10.1046/j.1365-3024.1999.00231.x
[73]   ANALYSIS OF SEQUENCE DIVERSITY IN THE PLASMODIUM-FALCIPARUM MEROZOITE SURFACE PROTEIN-1 (MSP-1) [J].
MILLER, LH ;
ROBERTS, T ;
SHAHABUDDIN, M ;
MCCUTCHAN, TF .
MOLECULAR AND BIOCHEMICAL PARASITOLOGY, 1993, 59 (01) :1-14
[74]   MALARIA PATHOGENESIS [J].
MILLER, LH ;
GOOD, MF ;
MILON, G .
SCIENCE, 1994, 264 (5167) :1878-1883
[75]   THE CLINICAL AND PARASITOLOGICAL PRESENTATION OF PLASMODIUM-FALCIPARUM MALARIA IN UGANDA IS UNAFFECTED BY HIV-1 INFECTION [J].
MULLER, O ;
MOSER, R .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1990, 84 (03) :336-338
[76]   PLASMODIUM-FALCIPARUM - THE HUMAN AGGLUTINATING ANTIBODY-RESPONSE TO THE INFECTED RED-CELL SURFACE IS PREDOMINANTLY VARIANT SPECIFIC [J].
NEWBOLD, CI ;
PINCHES, R ;
ROBERTS, DJ ;
MARSH, K .
EXPERIMENTAL PARASITOLOGY, 1992, 75 (03) :281-292
[77]  
NGUYENDINH P, 1987, B WORLD HEALTH ORGAN, V65, P607
[78]   Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand [J].
Nosten, F ;
Luxemburger, C ;
Kyle, DE ;
Ballou, WR ;
Wittes, J ;
Wah, E ;
Chongsuphajaisiddhi, T ;
Gordon, DM ;
White, NJ ;
Sadoff, JC ;
Heppner, DG ;
Bathe, K ;
Blood, J ;
Brockman, A ;
Cobley, UT ;
Hacking, D ;
Hogg, D ;
U, KH ;
Maelankiri, L ;
Chuanak, N ;
Permpanich, B ;
Price, R ;
Raimond, D ;
Schabenberger, O ;
Singharaj, P ;
Singhasivanon, P ;
Slight, T ;
Tulayon, S ;
Tway, KL ;
Ynint, T ;
VincentiDelmas, M ;
deVries, A ;
Webster, HK .
LANCET, 1996, 348 (9029) :701-707
[79]   Antibodies against merozoite surface protein (MSP)-119 are a major component of the invasion-inhibitory response in individuals immune to malaria [J].
O'Donnell, RA ;
de Koning-Ward, TF ;
Burt, RA ;
Bockarie, M ;
Reeder, JC ;
Cowman, AF ;
Crabb, BS .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (12) :1403-1412
[80]   Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal [J].
Oeuvray, C ;
Theisen, M ;
Rogier, C ;
Trape, JF ;
Jepsen, S ;
Druilhe, P .
INFECTION AND IMMUNITY, 2000, 68 (05) :2617-2620